FGC BOLSA - FGC FINANCIAL MARKETS INFO

Beth Pinsker 5-6 minutos - Source: Reuters NEW YORK (Reuters) - Your job does not have to be physically demanding to literally be a pain in the neck, or knee, or lower back. FILE PHOTO: A physical therapy room is seen at an onsite health clinic at the Intel corporate campus in Hillsboro, Oregon, U.S., April 25, 2018. REUTERS/Caroline Humer/File Photo Musculoskeletal conditions are among the top expenses for employee healthcare benefits, accounting for about a third of all worker injury and illness cases, according to the Occupational Safety and Health Administration (OSHA). With healthcare costs projected to rise 4.9% in 2020, according to Willis Towers Watson, many large companies are ready to try something new. They plan to spend more upfront to try to prevent higher costs later on. For conditions like chronic back pain, that means trying to prevent injuries or treat them with innovative physical therapy to avoid surgery a

Svea Herbst-Bayliss 4-5 minutes NEW YORK (Reuters) - PG&E Corp ( PCG.N ) shareholder Blue Mountain Capital Management LLC is preparing to launch a proxy fight to oust the embattled California utility owner’s board, arguing that the company is harming investors with its plan to seek bankruptcy protection in the wake of catastrophic wildfires. FILE PHOTO: PG&E works on power lines to repair damage caused by the Camp Fire in Paradise, California, U.S. November 21, 2018. REUTERS/Elijah Nouvelage/File Photo The hedge fund, which owns about 11 million PG&E shares, is trying to rally support from other shareholders to replace all 10 board members at this year’s annual meeting expected in May, according to a letter reviewed by Reuters. "We expect to announce the new slate no later than February, 21, 2019," the New York-based firm said in a letter here on Thursday. “In order to rebuild essential relationships and restore trust

Beth Pinsker 4-5 minutes NEW YORK (Reuters) - How U.S. schools calculate financial aid is so confusing that there is an entire industry devoted to unlocking its secrets with books, consultants and websites. Most parents are probably not aware that Stanford University in Palo Alto, California, or any school for that matter, consider the value of a home as part of the financial aid process. Stanford announced last month it was removing home equity from financial aid calculations. But should parents still consider strategies to look less “house rich” when applying for financial aid? “Even now, ten years after the housing bust, we still have families with homes worth significantly less than they paid, whereas the inflation calculator says they are worth more,” said Sean Moore, a certified financial planner in Boca Raton, Florida. One of Moore’s clients got an independent appraisal on their house when appealing an aid package, to show that they were less well off than it a

Suzanne Barlyn (Reuters) - Last March, a 103-year-old resident of a Sunrise Senior Living facility in Willowbrook, Illinois, went on a field trip to the movies.  Ruth Smith, who used a walker, fell down two concrete steps in the theater and died about six weeks later. Now Smith’s estate is suing Sunrise, saying that aides did not properly watch her. FILE PHOTO: A senior citizen, walks down the hallway with the aide of her walker to visit a neighbor at her independent living complex in Silver Spring, Maryland April 11, 2012. REUTERS/Gary Cameron/File Photo As the U.S. society ages, senior living communities are on the rise. So are claims and lawsuits against them. And when they lose, it is usually down to insurers to pay up. “It’s a tremendous opportunity that has pretty specific challenges,” said Brendan Gallagher, who heads the senior care business at insurance broker Arthur J. Gallagher & Co. ( AJG.N ) Some senior living facilities could see insuranc

Jamie McGeever LONDON (Reuters) - Hedge funds have struggled badly in 2018, but would be faring far worse were they not on the right side of two of the most reliable trades of the year: a flattening U.S. yield curve and a stronger dollar. FILE PHOTO: United States one dollar bills are seen on a light table at the Bureau of Engraving and Printing in Washington November 14, 2014. REUTERS/Gary Cameron/File Photo Both trends remain in place, and as the latest data show, speculators look like holding onto them for the rest of the year. Funds increased their net long dollar position against a range of developed and emerging-market currencies by nearly $2 billion to $32.09 billion in the week to Dec. 4, according to Commodity Futures Trading Commission figures. That’s the biggest cumulative bet on a rising dollar in three years. They also increased their net short position in two-year Treasuries by the second largest amount this year and upped their short pos

Chris Taylor NEW YORK (Reuters) - Here is some good news to hold onto this holiday season: Americans are giving more than ever. FILE PHOTO: U.S. Agency for International Development (USAID) Administrator Rajiv Shah gestures during the announcement of the U.S. Global Development Lab to help end extreme poverty by 2030, in New York April 3, 2014. REUTERS/Lucas Jackson Last year, Americans gave a total of $410 billion to worthy causes, according to Giving USA, surpassing $400 billion for the first time ever. And this year’s Giving Tuesday, a charity promotion on the Tuesday after Thanksgiving, is seeing pledges already totaling more than $380 million on just that one day, up 27 percent from the year before, according to a survey of major giving portals like Facebook, PayPal and Blackbaud. Who is helping steer the nation’s charitable dollars, and how did they get there? For the latest in Reuters’ First Jobs series, we talked to a few titans of philanthropy about their firs

Ben Hirschler The GlaxoSmithKline (GSK) logo on top of GSK Asia House is seen through vertical louvres in Singapore, March 21, 2018. REUTERS/Loriene Perera LONDON (Reuters) - GlaxoSmithKline ( GSK.L ) has agreed to buy U.S. cancer drug specialist Tesaro ( TSRO.O ) for $5.1 billion, marking a major biotech investment by the drugmaker as its seeks to rebuild its pharmaceuticals portfolio. Britain’s biggest drugmaker is paying $75 a share for the business, an 110 percent premium to the 30-day average price. News of the lofty valuation sent GSK shares down 4 percent on Monday. The deal gives GSK a marketed product for ovarian cancer, Zejula, which belongs to the promising new class of medicines called poly ADP ribose polymerase (PARP) inhibitors. GSK’s UK rival, AstraZeneca ( AZN.L ), sells the rival PARP drug Lynparza. Chief Executive Emma Walmsley has made replenishing GSK’s medicines cabinet her top priority and the company signaled its inten